Medicine and Dentistry
Neoplasm
100%
Testis Cancer
73%
Transitional Cell Carcinoma
72%
Cystectomy
69%
Diseases
64%
Prostate Cancer
62%
Recurrent Disease
57%
Bladder
55%
Bladder Cancer
51%
Retroperitoneal Lymph Node Dissection
50%
Prostatectomy
38%
Transurethral Resection
34%
Germinoma
32%
Prostate Specific Antigen
31%
Biopsy Technique
28%
Orchiectomy
28%
Clinical Stage
27%
Urinary System
26%
Bladder Tumor
25%
Metastatic Carcinoma
24%
Overall Survival
24%
Testis Tumor
23%
Muscle Invasive Bladder Cancer
18%
Malignant Neoplasm
17%
Urinary Diversion
17%
Neobladder
17%
Transrectal Ultrasonography
16%
Prostate Hypertrophy
16%
Prostate Biopsy
15%
Cancer
15%
Prospective Study
15%
Urinary Tract Infection
15%
Magnetic Resonance Imaging
15%
Prostate Specific Membrane Antigen
14%
Hazard Ratio
14%
Intravesical Drug Administration
14%
Health Care Cost
13%
Minimal Residual Disease
13%
Immunotherapy
12%
Surgeon
12%
Adjuvant Chemotherapy
12%
Pelvis
12%
Disease Exacerbation
11%
Mitomycin
11%
Positron Emission Tomography-Computed Tomography
11%
Quality of Life
11%
Erectile Dysfunction
11%
Ileal Conduit
11%
Testes
11%
Gallium 68
11%
Keyphrases
Tumor
75%
Radical Cystectomy
55%
Bladder Cancer
49%
Testis Cancer
44%
Prostate Cancer
38%
Prostate-specific Antigen
37%
Testicular Cancer
33%
Chemotherapy
32%
Retroperitoneal Lymph Node Dissection (RPLND)
31%
Erectile Dysfunction
30%
Prostate
28%
Radical Prostatectomy
25%
Transurethral Resection of Bladder Tumor (TURBT)
24%
Overall Survival
24%
Bladder
24%
Bacillus Calmette
22%
Nonseminomatous
22%
Resection
22%
Non-muscle Invasive Bladder Cancer (NMIBC)
22%
Cystectomy
22%
Ureteral Stent
20%
Upper Tract Urothelial Carcinoma
20%
T1G3
20%
Oncological Outcomes
19%
High Risk
19%
Confidence Interval
19%
Benign Prostatic Hyperplasia
19%
Muscle-invasive Bladder Cancer
19%
Prostate Cancer Screening
19%
Urothelial Carcinoma
18%
Recurrent Disease
18%
Late Relapse
18%
Hazard Ratio
17%
Testicular Germ Cell Tumor
16%
Patients with Prostate Cancer
16%
Orchiectomy
16%
Multiparametric MRI (mpMRI)
16%
Post-chemotherapy
16%
Testicular Tumor
15%
Transitional Cell Carcinoma
15%
Papaverine
15%
Gonadotropin-releasing Hormone
15%
Post-chemotherapy Retroperitoneal Lymph Node Dissection
15%
Disease Progression
14%
Risk Factors
14%
Cancer Patients
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Metastasis
14%
Stent
14%
Transurethral Resection
13%